There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did
not persist in 2024. Tough refinancing conditions have been holding the market back, according to the German website.
But if an interest rate cut materializes over the summer, the outlook would look a lot brighter, according to commentator André Will-Laudien, who added Vidac Pharma to his “Buy” list, together with a selected few other stocks that would profit from an upturn.
Read the Article
News & Events